Floatz logo

Ponatinib

Newly Diagnosed

Institute of Hematology and Blood Transfusion, Czech RepublicSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

31 Active assets in the Newly Diagnosed cohort.

Asset / SponsorPhaseRating
cc-5013
The First Affiliated Hospital of Soochow University
Phase 4BB
DEXAMETHASONE
The First Affiliated Hospital of Soochow University
Phase 4BB
FILGRASTIM
The First Affiliated Hospital of Soochow University
Phase 4BB
Bortezomib
The First Affiliated Hospital of Soochow University
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
The First Affiliated Hospital of Soochow University
Phase 4B

View all 34 →

Same molecule, other indications

Ponatinib is also rated in:

chronic myeloid leukemiaDormant
BB
Indicative ·
66 / 100
View asset →
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
65 / 100
View asset →
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →